Trial Profile

IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Liver cancer
Focus Adverse reactions; Therapeutic Use
Acronyms IMMUNIB

Most Recent Events

24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
23 Mar 2023 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results assessing the efficacy of nivolumab in combination with lenvatinib as first line treatment in patients with advanced hepatocellular carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com